Skip to main content
. 2019 May 30;44(2):437–446. doi: 10.3892/ijmm.2019.4220

Figure 5.

Figure 5

Quinalizarin enhances the suppression of cell viability mediated by icotinib in both primary and secondary drug resistant cell lines. The cells were treated with different concentrations of quinalizarin. The control group was treated with the equal concentration of dimethyl sulfoxide. The viability of (A) HCC827, (B) A549, (C) H1650 and (D) H1975 cells was assessed using an MTT assay after 48 h. The mean ± standard deviation was calculated from three independent experiments. (*P<0.05, **P<0.01, ***P<0.001).